BACKGROUND: Our group has previously shown that prostate-specific antigen (PSA) velocity (PSAV) is associated with the presence of life-threatening prostate cancer. Less is known about the relative utility of pretreatment PSA doubling time (PSA DT) to predict tumor aggressiveness. OBJECTIVE: To compare the utility of PSAV and PSA DT for the prediction of life-threatening prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: From the Baltimore Longitudinal Study of Aging, we identified 681 men with serial PSA measurements. MEASUREMENTS: Receiver operating characteristic analysis was used to evaluate the relationship between PSAV, PSA DT, and the presence of high-risk disease. RESULTS AND LIMITATIONS: Within the period of 5 yr prior to diagnosis, PSAV was significantly higher among men with high-risk or fatal prostate cancer than men without it. By contrast, PSA DT was not significantly associated with high-risk or fatal disease. On multivariate analysis, including age, date of diagnosis, and PSA, the addition of PSAV significantly improved the concordance index from 0.85 to 0.88 (p<0.001), whereas PSA DT did not. CONCLUSIONS: These data suggest that PSAV is more useful than PSA DT in the pretreatment setting to help identify those men with life-threatening disease.
BACKGROUND: Our group has previously shown that prostate-specific antigen (PSA) velocity (PSAV) is associated with the presence of life-threatening prostate cancer. Less is known about the relative utility of pretreatment PSA doubling time (PSADT) to predict tumor aggressiveness. OBJECTIVE: To compare the utility of PSAV and PSADT for the prediction of life-threatening prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: From the Baltimore Longitudinal Study of Aging, we identified 681 men with serial PSA measurements. MEASUREMENTS: Receiver operating characteristic analysis was used to evaluate the relationship between PSAV, PSADT, and the presence of high-risk disease. RESULTS AND LIMITATIONS: Within the period of 5 yr prior to diagnosis, PSAV was significantly higher among men with high-risk or fatal prostate cancer than men without it. By contrast, PSADT was not significantly associated with high-risk or fatal disease. On multivariate analysis, including age, date of diagnosis, and PSA, the addition of PSAV significantly improved the concordance index from 0.85 to 0.88 (p<0.001), whereas PSADT did not. CONCLUSIONS: These data suggest that PSAV is more useful than PSADT in the pretreatment setting to help identify those men with life-threatening disease.
Authors: Ali Khatami; Khatami Ali; Gunnar Aus; Aus Gunnar; Jan-Erik Damber; Damber Jan-Erik; Hans Lilja; Lilja Hans; Pär Lodding; Lodding Pär; Jonas Hugosson; Hugosson Jonas Journal: Int J Cancer Date: 2007-01-01 Impact factor: 7.396
Authors: Stijn Roemeling; Monique J Roobol; Stijn H de Vries; Tineke Wolters; Claartje Gosselaar; Geert J L H van Leenders; Fritz H Schröder Journal: Eur Urol Date: 2006-12-05 Impact factor: 20.096
Authors: H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh Journal: JAMA Date: 1992 Apr 22-29 Impact factor: 56.272
Authors: Anthony V D'Amico; Judd W Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Natl Cancer Inst Date: 2003-09-17 Impact factor: 13.506
Authors: Corey A Carter; Timothy Donahue; Leon Sun; Hongyu Wu; David G McLeod; Christopher Amling; Raymond Lance; John Foley; Wade Sexton; Leo Kusuda; Andrew Chung; Douglas Soderdahl; Stephen Jackmaan; Judd W Moul Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544
Authors: Frederik A van Delft; Milou Schuurbiers; Mirte Muller; Sjaak A Burgers; Huub H van Rossum; Maarten J IJzerman; Hendrik Koffijberg; Michel M van den Heuvel Journal: Heliyon Date: 2022-10-04